profit from every $100 of sales.
$0$100
Adicet Bio
$2.99-0.33% today
-71.1% in 1 year
1-year low $2.921-year high $10.98
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Adicet Bio sold, what it kept, and what it did with the cash.
Sales went from $25.0 million in 2022 to $0 in 2025, with -$117 million of profit last year.
SalesProfit
Adicet Bio vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Adicet Bio | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads Adicet Bio's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 25 | 0 | 0 | 0 | |
| – | – | – | – | |
| -73 | -133 | -128 | -122 | |
| -67 | -137 | -111 | -110 | |
| -70 | -143 | -117 | -117 | |
| -27.20 | -52.96 | -21.28 | -16.95 | |
| – | – | – | – | |
| -290.3% | – | – | – | |
| -279.3% | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 331 | 207 | 220 | 192 |
| Cash | 258 | 160 | 56 | 39 |
| Total debt | 21 | 21 | 17 | 15 |
| Total liabilities | 38 | 37 | 34 | 33 |
| 292 | 170 | 187 | 159 | |
| 3 | 3 | 5 | 7 | |
| -17.6% | -59.0% | -45.4% | -53.0% | |
| -23.9% | -83.8% | -62.8% | -73.4% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -45 | -94 | -92 | -95 | |
| 17 | 4 | 1 | 2 | |
| -62 | -98 | -93 | -97 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 17 | 20 | 22 | 14 |
Valuation
- –
- –
- –
- 0.4×
- 1.1×
- –
- –
- -219.9%
- -249.3%
- 0.0%
Profitability
- 0.0%
- -290.3%
- -279.3%
- 0.0%
- -70.2%
- -48.1%
- -83.0%
- -60.7%
- -71.5%
- –
Growth
- –
- –
- −3.7%
- –
- +37.4%
Financial health
- -3.5×
- 0.09
- 7.7%
- -3,392.1×
- 7.47
- 7.47
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 3%of 958
What analysts expect
- Average price target
- $18.00
- Range
- $18.00 – $18.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 13, 2026 | -1.88 | -2.93 | +35.8% |
| Mar 12, 2026 | -2.94 | -3.23 | +9.0% |
| Nov 5, 2025 | -4.64 | -4.16 | −11.5% |
| Aug 7, 2025 | -5.44 | -5.12 | −6.3% |
| May 6, 2025 | -4.96 | -5.44 | +8.8% |
| Mar 6, 2025 | -5.12 | -5.92 | +13.5% |
| Nov 6, 2024 | -5.44 | -5.76 | +5.6% |
| Aug 13, 2024 | -5.28 | -5.60 | +5.7% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
40No pass
Benjamin Graham
78Pass
Philip Fisher
33No pass
Peter Lynch
48No pass
Joel Greenblatt
0No pass
Charlie Munger
28No pass
Terry Smith
26No pass
Questions about Adicet Bio
Is Adicet Bio a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Adicet Bio AI analysis
What does Adicet Bio do?
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. It is in Biotechnology.
Does Adicet Bio pay a dividend?
No. Adicet Bio does not pay a dividend at the moment.
Is Adicet Bio stock halal?
No. Adicet Bio does not pass our halal screen: its debt is 53% of its market value, at or above the 33% limit. How we check
How has Adicet Bio stock done over the past year?
Down 71.1% over the past twelve months, to $2.99. It traded between $2.92 and $10.98 and is 72.8% below its high.
Who are Adicet Bio's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Adicet Bio's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.